Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + AK105 in advanced head, neck, and thoracic tumors
CTR20192550Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in head and neck squamous cell carcinoma (HNSCC), head and neck cancer (HNC), small cell lung cancer (SCLC), Non-small cell lung cancer (NS-NSCLC), Pulmonary squamous cell carcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2019; status: completed.
02
Drugs
penpulimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)small cell lung cancer (SCLC)Non-small cell lung cancer (NS-NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20192550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192550.